Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for satralizumab

  1. Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)

    NICE is unable to make a recommendation on satralizumab (Enspryng) for preventing relapses in neuromyelitis optica spectrum disorders in adults

    Technology appraisal guidance
    Published
    27 March 2024

    Sections for TA960

  2. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development